ATM Sales Drive Series B Warrant Price Down to $1.22 for Sunshine Biopharma

summarizeSummary

Sunshine Biopharma disclosed that its Series B Warrant exercise price has been reduced to $1.2202 due to recent sales under its $4 million at-the-market equity program, increasing potential dilution.

check_boxKey Events · Financing and Capital Events · SBFM

• Series B Warrant Price Cut

  The exercise price has been reduced to $1.2202 from a prior higher level due to recent ATM sales, increasing potential dilution for existing shareholders.

• ATM Program Active

  The $4 million at-the-market facility established July 20, 2026 is being utilized, triggering the warrant price adjustment.

• Financial Distress Context

  This follows a 1-for-10 reverse split, a $6 million dilutive offering, and a $1.06 million legal settlement, highlighting the company's urgent need for capital.

• Potential Further Adjustments

  The Series B Warrants are subject to further price reductions based on future equity sales, creating ongoing dilution risk.

auto_awesomeAnalysis · SBFM · Life Sciences

Active use of the company's at-the-market equity facility has pushed the Series B Warrant exercise price down to $1.2202. This adjustment is a direct result of the $4 million ATM program launched in July 2026. While the ATM itself was previously disclosed, the price cut represents a new material development—it raises the potential dilution from these warrants and confirms that the company is tapping the facility, which could add further pressure on the stock. The move comes against a backdrop of severe financial distress, including a recent reverse split, a dilutive $6 million offering, and a legal settlement.